"EDTA" redirects here. For other uses, see EDTA (disambiguation).
Ethylenediaminetetraacetic acid
|
Disodium EDTA
|
Names |
Systematic IUPAC name
2-({2-[Bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetic acid
|
Other names
- Diaminoethane-tetraacetic acid
- Edetic acid
- Ethylenedinitrilo-tetraacetic acid
- Versene
|
Identifiers |
CAS Number
|
60-00-4 Y |
Abbreviations |
EDTA, H4EDTA |
Beilstein Reference
|
1716295 |
ChEBI |
CHEBI:42191 Y |
ChEMBL |
ChEMBL858 Y |
ChemSpider |
5826 Y |
DrugBank |
DB00974 Y |
EC Number |
200-449-4 |
Gmelin Reference
|
144943 |
Jmol 3D model |
Interactive image
Interactive image |
KEGG |
D00052 Y |
MeSH |
Edetic+Acid |
PubChem |
6049 |
RTECS number |
AH4025000 |
UNII |
9G34HU7RV0 Y |
UN number |
3077 |
InChI
-
InChI=1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20) Y
Key: KCXVZYZYPLLWCC-UHFFFAOYSA-N Y
|
SMILES
-
[o]:c(:[oH])CN(CCN(Cc(:[o]):[oH])Cc(:[o]):[oH])Cc(:[o]):[oH]
-
OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
|
Properties |
Chemical formula
|
C10H16N2O8 |
Molar mass |
292.24 g·mol−1 |
Appearance |
Colourless crystals |
Density |
860 mg mL−1 (at 20 °C) |
log P |
−0.836 |
Acidity (pKa) |
1.782 |
Basicity (pKb) |
12.215 |
Thermochemistry |
Std enthalpy of
formation (ΔfHo298)
|
−1.7654 to −1.7580 MJ mol−1 |
Std enthalpy of
combustion (ΔcHo298)
|
−4.4617 to −4.4545 MJ mol−1 |
Pharmacology |
ATC code
|
S01XA05 (WHO) V03AB03 (WHO) (salt) |
Routes of
administration
|
- Intramuscular
- Intravenous
|
Hazards |
GHS pictograms |
|
GHS signal word |
WARNING |
GHS hazard statements
|
H319 |
GHS precautionary statements
|
P305+351+338 |
EU classification (DSD)
|
Xi |
R-phrases |
R36 |
S-phrases |
(S2), S26 |
NFPA 704 |
|
Lethal dose or concentration (LD, LC): |
LD50 (median dose)
|
1000 mg/kg (oral, rat)[1] |
Related compounds |
Related alkanoic acids
|
|
Related compounds
|
- Triethylenetetramine
- Tetraacetylethylenediamine
- PMDTA
- Bis-tris propane
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
N verify (what is YN ?) |
Infobox references |
|
|
Ethylenediaminetetraacetic acid, widely abbreviated as EDTA (for other names, see Table), is an aminopolycarboxylic acid and a colourless, water-soluble solid. Its conjugate base is named ethylenediaminetetraacetate. It is widely used to dissolve limescale. Its usefulness arises because of its role as a hexadentate ("six-toothed") ligand and chelating agent, i.e., its ability to "sequester" metal ions such as Ca2+ and Fe3+. After being bound by EDTA, metal ions remain in solution but exhibit diminished reactivity. EDTA is produced as several salts, notably disodium EDTA and calcium disodium EDTA.
It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.[2]
Contents
- 1 Uses
- 1.1 Industry
- 1.2 Medicine
- 1.3 Alternative medicine
- 1.4 Cosmetics
- 1.5 Laboratory applications
- 2 Side effects
- 3 Synthesis
- 4 Nomenclature
- 5 Coordination chemistry principles
- 6 Environmental fate
- 6.1 Abiotic degradation
- 6.2 Biodegradation
- 7 Alternatives
- 7.1 Iminodisuccinic acid (IDS)
- 7.2 Polyaspartic acid
- 7.3 Ethylenediamine-N,N′-disuccinic acid (EDDS)
- 7.4 Methylglycinediacetic acid (MGDA)
- 7.5 L-glutamic acid N,N-diacetic acid, tetrasodium salt (GLDA)
- 8 Methods of detection and analysis
- 9 References
- 10 External links
Uses
Industry
In industry, EDTA is mainly used to sequester metal ions in aqueous solution. In the textile industry, it prevents metal ion impurities from modifying colors of dyed products. In the pulp and paper industry, EDTA inhibits the ability of metal ions, especially Mn2+, from catalyzing the disproportionation of hydrogen peroxide, which is used in "chlorine-free bleaching." In a similar manner, EDTA is added to some food as a preservative or stabilizer to prevent catalytic oxidative decoloration, which is catalyzed by metal ions.[3] In soft drinks containing ascorbic acid and sodium benzoate, EDTA mitigates formation of benzene (a carcinogen).[4]
The reduction of water hardness in laundry applications and the dissolution of scale in boilers both rely on EDTA and related complexants to bind Ca2+, Mg2+, as well as other metal ions. Once bound to EDTA, these metal centers tend not to form precipitates or to interfere with the action of the soaps and detergents. For similar reasons, cleaning solutions often contain EDTA.
The solubilization of ferric ions, at or below near neutral pH can be accomplished using EDTA. This property is useful in agriculture including hydroponics. However, given the pH dependence of ligand formation, EDTA is not helpful for improving Fe solubility in above neutral soils.[5] Otherwise, at near-neutral pH and above, iron(III) forms insoluble salts, which are less bioavailable to susceptible plant species. Aqueous [Fe(edta)]− is used for removing ("scrubbing") hydrogen sulfide from gas streams. This conversion is achieved by oxidizing the hydrogen sulfide to elemental sulfur, which is non-volatile:
- 2 [Fe(edta)]− + H2S → 2 [Fe(edta)]2− + S + 2 H+
In this application, the ferric center is reduced to its ferrous derivative, which can then be reoxidized by air. In similar manner, nitrogen oxides are removed from gas streams using [Fe(edta)]2−. The oxidizing properties of [Fe(edta)]− are also exploited in photography, where it is used to solubilize silver particles.[6]
EDTA was used in the separation of the lanthanide metals by ion-exchange chromatography. Perfected by F.H. Spedding et al. in 1954, the method relies on the steady increase in stability constant of the lanthanide EDTA complexes with atomic number. Using sulfonated polystyrene beads and copper(II) as a retaining ion, EDTA causes the lanthanides to migrate down the column of resin while separating into bands of pure lanthanide. The lanthanides elute in order of decreasing atomic number. Due to the expense of this method, relative to counter-current solvent extraction, ion-exchange is now used only to obtain the highest purities of lanthanide (typically greater than 4N, 99.99%).[citation needed]
Medicine
EDTA is used to bind metal ions in the practice of chelation therapy, e.g., for treating mercury and lead poisoning.[7] It is used in a similar manner to remove excess iron from the body. This therapy is used to treat the complication of repeated blood transfusions, as would be applied to treat thalassaemia. The U.S. FDA approved the use of EDTA for lead poisoning[8] on July 16, 1953, under the brand name of Versenate,[9] which was licensed to the pharmaceutical company Riker.
From 2003 to 2005, deaths of 3 individuals as a result of cardiac arrest caused by hypocalcemia during chelation therapy with EDTA were reported to the Centers for Disease Control and Prevention.[10]
Dentists and endodontists use EDTA solutions to remove inorganic debris (smear layer) and lubricate the canals in endodontics. This procedure helps prepare root canals for obturation. Furthermore, EDTA solutions with the addition of a surfactant loosen up calcifications inside a root canal and allow instrumentation (canals shaping) and facilitate apical advancement of a file in a tight/calcified root canal towards the apex. It serves as a preservative (usually to enhance the action of another preservative such as benzalkonium chloride or thiomersal) in ocular preparations and eyedrops. In evaluating kidney function, the complex [Cr(edta)]− is administered intravenously and its filtration into the urine is monitored. This method is useful for evaluating glomerular filtration rate.[11]
EDTA is used extensively in the analysis of blood. It is an anticoagulant for blood samples for CBC/FBEs.
EDTA is a slime dispersant, and has been found to be highly effective in reducing bacterial growth during implantation of intraocular lenses (IOLs).[12]
Alternative medicine
Some alternative practitioners believe EDTA acts as an antioxidant, preventing free radicals from injuring blood vessel walls, therefore reducing atherosclerosis.[7] These ideas are as yet unsupported by scientific studies, and seem to contradict some currently accepted principles.[13] The U.S. FDA has not approved it for the treatment of atherosclerosis.[14]
Cosmetics
In shampoos, cleaners, and other personal care products, EDTA salts are used as a sequestering agent to improve their stability in air.[15]
Laboratory applications
In the laboratory, EDTA is widely used for scavenging metal ions: In biochemistry and molecular biology, ion depletion is commonly used to deactivate metal-dependent enzymes, either as an assay for their reactivity or to suppress damage to DNA or proteins.[16] In analytical chemistry, EDTA is used in complexometric titrations and analysis of water hardness or as a masking agent to sequester metal ions that would interfere with the analyses. EDTA finds many specialized uses in the biomedical laboratories, such as in veterinary ophthalmology as an anticollagenase to prevent the worsening of corneal ulcers in animals. In tissue culture EDTA is used as a chelating agent that binds to calcium and prevents joining of cadherins between cells, preventing clumping of cells grown in liquid suspension, or detaching adherent cells for passaging. In histopathology, EDTA can be used as a decalcifying agent making it possible to cut sections using a microtome once the tissue sample is demineralised. EDTA is also known to inhibit a range of metallopeptidases, the method of inhibition occurs via the chelation of the metal ion required for catalytic activity.[17] EDTA can also be used to test for bioavailability of heavy metals in sediments. However, EDTA may influence the bioavailability of metals in solution, which may pose concerns regarding its effects in the environment, especially given its widespread uses and applications.
Side effects
EDTA exhibits low acute toxicity with LD50 (rat) of 2.0 g/kg to 2.2 g/kg.[6] It has been found to be both cytotoxic and weakly genotoxic in laboratory animals. Oral exposures have been noted to cause reproductive and developmental effects.[15] The same study by Lanigan[15] also found that both dermal exposure to EDTA in most cosmetic formulations and inhalation exposure to EDTA in aerosolized cosmetic formulations would produce exposure levels below those seen to be toxic in oral dosing studies.
Synthesis
The compound was first described in 1935 by Ferdinand Münz, who prepared the compound from ethylenediamine and chloroacetic acid.[18] Today, EDTA is mainly synthesised from ethylenediamine (1,2-diaminoethane), formaldehyde, and sodium cyanide.[19] This route yields the sodium salt, which can be converted in a subsequent step into the acid forms:
- H2NCH2CH2NH2 + 4 CH2O + 4 NaCN + 4 H2O → (NaO2CCH2)2NCH2CH2N(CH2CO2Na)2 + 4 NH3
- (NaO2CCH2)2NCH2CH2N(CH2CO2Na)2 + 4 HCl → (HO2CCH2)2NCH2CH2N(CH2CO2H)2 + 4 NaCl
This process is used to produce about 80 thousand tonnes each year. Impurities cogenerated by this route include glycine and nitrilotriacetic acid; they arise from reactions of the ammonia coproduct.[6]
Nomenclature
To describe EDTA and its various protonated forms, chemists distinguish between EDTA4−, the conjugate base that is the ligand, and H4EDTA, the precursor to that ligand. At very low pH (very acidic conditions) the fully protonated H6EDTA2+ form predominates, whereas at very high pH or very basic condition, the fully deprotonated EDTA4− form is prevalent. In this article, the term EDTA is used to mean H4−xEDTAx−, whereas in its complexes EDTA4− stands for the tetra-deprotonated ligand.
Coordination chemistry principles
In coordination chemistry, EDTA4− is a member of the aminopolycarboxylic acid family of ligands. EDTA4− usually binds to a metal cation through its two amines and four carboxylates. Many of the resulting coordination compounds adopt octahedral geometry. Although of little consequence for its applications, these octahedral complexes are chiral. The anion [Co(EDTA)]− has been resolved into enantiomers.[20] Many complexes of EDTA4− adopt more complex structures due to either the formation of an additional bond to water, i.e. seven-coordinate complexes, or the displacement of one carboxylate arm by water. The Fe(III) complex of EDTA is seven-coordinate.[21] Early work on the development of EDTA was undertaken by Gerold Schwarzenbach in the 1940s.[22] EDTA forms especially strong complexes with Mn(II), Cu(II), Fe(III), Pb (II) and Co(III).[23]
Several features of EDTA's complexes are relevant to its applications. First, because of its high denticity, this ligand has a high affinity for metal cations:
- [Fe(H2O)6]3+ + H4EDTA ⇌ [Fe(EDTA)]− + 6 H2O + 4 H+ (Keq = 1025.1)
Written in this way, the equilibrium quotient shows that metal ions compete with protons for binding to EDTA. Because metal ions are extensively enveloped by EDTA, their catalytic properties are often suppressed. Finally, since complexes of EDTA4− are anionic, they tend to be highly soluble in water. For this reason, EDTA is able to dissolve deposits of metal oxides and carbonates.
Environmental fate
Abiotic degradation
EDTA is in such widespread use that questions have been raised whether it is a persistent organic pollutant. While EDTA serves many positive functions in different industrial, pharmaceutical and other avenues, the longevity of EDTA can pose serious issues in the environment. The degradation of EDTA is slow. It mainly occurs abiotically in the presence of sunlight.[24]
The most important process for the elimination of EDTA from surface waters is direct photolysis at wavelengths below 400 nm.[25] Depending on the light conditions, the photolysis half-lives of Fe(III) EDTA in surface waters can range as low as 11.3 minutes up to more than 100 hours.[26] Degradation of FeEDTA, but not EDTA itself, produces Fe complexes of ED3A, EDDA, and EDMA – 92% of EDDA and EDMA biodegrades in 20 hours while ED3A displays significantly higher resistance. Many environmentally abundant EDTA species (e.g., Mg2+, Ca2+) are more persistent.
Biodegradation
In many industrial wastewater treatment plants, EDTA elimination can be achieved at about 80% using microorganisms.[27] Resulting byproducts are ED3A and IDA – suggesting that both the backbone and acetyl groups were attacked. Some microorganisms have even been discovered to form nitrates out of EDTA but degrade optimally at moderately alkaline conditions of pH 9.0–9.5.[28]
Several bacterial strains isolated from sewage treatment plants efficiently degrade EDTA. Specific strains include Agrobacterium radiobacter ATCC 55002[29] and the sub-branches of Proteobacteria like BNC1, BNC2 [30] and strain DSM 9103.[31] The three strains share similar properties of aerobic respiration and are classified as gram-negative bacteria. Unlike photolysis, the chelated species is not exclusive to Fe(III) in order to be degraded. Rather, each strain uniquely consumes varying metal-EDTA complexes through several enzymatic pathways. Agrobacterium radiobacter only degrades Fe(III) EDTA [30] while BNC1 and DSM 9103 are not capable of degrading Fe(III) EDTA and are more suited for CaEDTA, BaEDTA, MgEDTA and MnEDTA.[32] EDTA complexes require dissociation before degradation .
Alternatives
Interest in environmental safety has brought up concerns about biodegradability in aminopolycarboxylates such as EDTA. For example, under the International Organization for Standardization 28-day 7827 test Austrian paper and pulp industries must use chelating agents that have biodegradation levels over 70% to 80%.[33] An increased interest in safety has led to the development and research of alternative chelating ligands which can still bind strongly to metal ions but also have a higher biodegradability and a lower content of nitrogen.[33]
Iminodisuccinic acid (IDS)
Commercially used since 1998, iminodisuccinic (IDS) acid biodegrades about 80% after only 7 days. IDS binds to calcium exceptionally well and forms stable compounds with other heavy metal ions. In addition to having a lower toxicity after chelation, the production of IDS is environment-friendly.[33] Specifically, IDS is degraded through the use of IDS-epimerase and C–N lyase found in Agrobacterium tumefaciens (BY6) which can be harvested on a large scale. Additionally, the reactions catalyzed by both enzymes do not require any cofactors and can thus be applied directly.[34]
Polyaspartic acid
Polyaspartic acid, like IDS binds to calcium and other heavy metal ions. It has a higher value of 7.2 meq/g than does EDTA, which only has 6.0 meq/g.[33] While it has a higher theoretical capacity, in practical applications it exhibits low efficiency in lower ion concentration solutions. It has many practical applications including corrosion inhibitors, waste water additives, and agricultural polymers. A Polyaspartic acid-based laundry detergent was the first laundry detergent in the world to receive the EU flower ecolabel.[33]
Ethylenediamine-N,N′-disuccinic acid (EDDS)
As a structural isomer of EDTA, ethylenediamine-N,N′-disuccinic acid can exist three isomers: (S,S), (R,S)/(S,R) and (R,R), but only the S,S-isomer is readily biodegradable. EDDS exhibits a surprisingly high rate biodegradation at 83% in 20 days. Biodegradation rates also varies the different metal ions chelated. For example, the complexes of lead and zinc with EDDS have relatively the same stability but the lead complex is biodegrades more efficiently than the zinc complex.[33] As of 2002, EDDS has been commercially prominent in Europe on a large scale with an estimated demand rate increase of about 15% each year.[33]
Methylglycinediacetic acid (MGDA)
Produced from BASF, methylglycinediacetic acid (MGDA) is produced from glycine.[33] MGDA has a high rate of biodegradation >68%, but unlike many other chelating agents can degrade without the assistance of adapted bacteria. Additionally, unlike EDDS or IDS, MGDA can withstand higher temperatures while maintaining a high stability as well as the entire pH range. As a result, the chelating strength of MGDA is stronger than many commercial chelating agents.[33]
L-glutamic acid N,N-diacetic acid, tetrasodium salt (GLDA)
Aminopolycarboxylate-based chelates control metal ions in water-based systems.
Methods of detection and analysis
The most sensitive method of detecting and measuring EDTA in biological samples is selected-reaction-monitoring capillary-electrophoresis mass-spectrometry (abbreviation SRM-CE/MS), which has a detection limit of 7.3 ng/mL in human plasma and a quantitation limit of 15 ng/mL.[35] This method works with sample volumes as small as ~7–8 nL.[35]
EDTA has also been measured in non-alcoholic beverages using high performance liquid chromatography (HPLC) at a level of 2.0 μg/mL.[36][37]
References
- ^ Substance Name: Sodium calcium edetate. NIH.gov
- ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
- ^ Furia T (1964). "EDTA in Foods – A technical review". Food Technology 18 (12): 1874–1882.
- ^ US Food and Drug Administration: Center for Food Safety and Applied Nutrition Questions and Answers on the Occurrence of Benzene in Soft Drinks and Other Beverages
- ^ Norvell, W. A.; Lindsay, W. L. (1969). "Reactions of EDTA Complexes of Fe, Zn, Mn, and Cu with Soils". Soil Science Society of America Journal 33: 86. doi:10.2136/sssaj1969.03615995003300010024x.
- ^ a b c Hart, J. Roger (2005) "Ethylenediaminetetraacetic Acid and Related Chelating Agents" in Ullmann's Encyclopedia of Industrial Chemistry, Wiley-VCH, Weinheim. doi:10.1002/14356007.a10_095
- ^ a b DeBusk, Ruth; et al. (2002). "Ethylenediaminetetraacetic acid (EDTA)". University of Maryland Medical Center.
- ^ "Calcium Disodium Versenate (Edetate Calcium Disodium) Injection [Graceway Pharmaceuticals, Llc]". Dailymed.nlm.nih.gov. Retrieved 2013-01-01.
- ^ "Drugs@FDA: FDA Approved Drug Products". Accessdata.fda.gov. Retrieved 2013-01-01.
- ^ Brown, M. J.; Willis, T.; Omalu, B.; Leiker, R. (2006). "Deaths Resulting from Hypocalcemia After Administration of Edetate Disodium: 2003–2005" (Full free text). Pediatrics 118 (2): e534. doi:10.1542/peds.2006-0858. PMID 16882789.
- ^ Shirley, D.G.; Walter, S.J.; Noormohamed, F.H. (2002). "Natriuretic effect of caffeine: assessment of segmental sodium reabsorption in humans". Clinical Science 103 (5): 461–466. doi:10.1042/CS20020055. PMID 12401118.
- ^ Kadry, A. A.; Fouda, S. I.; Shibl, A. M.; Abu El-Asrar, A. A. (2009). "Impact of slime dispersants and anti-adhesives on in vitro biofilm formation of Staphylococcus epidermidis on intraocular lenses and on antibiotic activities". Journal of Antimicrobial Chemotherapy 63 (3): 480. doi:10.1093/jac/dkn533. PMID 19147522.
- ^ Green, Saul; Wallace Sampson (December 14, 2002). "EDTA Chelation Therapy for Atherosclerosis And Degenerative Diseases: Implausibility and Paradoxical Oxidant Effects". Quackwatch. Retrieved 16 December 2009.
- ^ "Postmarket Drug Safety Information for Patients and Providers > Questions and Answers on Edetate Disodium (marketed as Endrate and generic products)". U.S. Food and Drug Administration.
- ^ a b c Lanigan RS, Yamarik TA (2002). "Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA". Int J Toxicol. 21 Suppl 2 (5): 95–142. doi:10.1080/10915810290096522. PMID 12396676.
- ^ Dominguez, K; Ward, WS (December 2009). "A novel nuclease activity that is activated by Ca2+ chelated to EGTA". Systems Biology in Reproductive Medicine 55 (5–6): 193–99. doi:10.3109/19396360903234052.
- ^ Auld, D. S. (1995). "Removal and replacement of metal ions in metallopeptidases". Methods in enzymology 248: 228–42. PMID 7674923.
- ^ Münz, F. (1938) "Polyamino carboxylic acids to I. G. Farbenindustrie, U.S. Patent 2,130,505, DE 718 981, 1935.
- ^ Industrial Synthesis of EDTA. chm.bris.ac.uk
- ^ Kirchner, S; Gyarfas, Eleonora C. (1957). "Barium (Ethylenediaminetetracetato) Cobalt(III) 4-Hydrate". Inorganic Syntheses. Inorganic Syntheses 5: 186–188. doi:10.1002/9780470132364.ch52. ISBN 9780470132364.
- ^ López-Alcalá, J. M.; Puerta-Vizcaíno, M. C.; González-Vílchez, F.; Duesler, E. N.; Tapscott, R. E. (1984). "A redetermination of sodium aqua[ethylenediaminetetraacetato(4−)]ferrate(III) dihydrate, Na[Fe(C10H12N2O8)(H2O)]·2H2O". Acta Crystallogr C 40 (6): 939–941. doi:10.1107/S0108270184006338.
- ^ Sinex, Scott A. EDTA – A Molecule with a Complex Story. chm.bris.ac.uk
- ^ Holleman, A. F.; Wiberg, E. (2001). Inorganic Chemistry. San Diego: Academic Press. ISBN 0-12-352651-5.
- ^ Bucheli-Witschel, M.; Egli, T. (2001), "DAB: Environmental Fate and Microbial Degradation of Aminopolycarboxylic Acids", FEMS Microbiology Reviews 25 (1): 69–106, doi:10.1111/j.1574-6976.2001.tb00572.x, PMID 11152941
- ^ Kari, F.G (1994). Umweltverhalten von Ethylenediaminetetraacetate (EDTA) under spezieller Berucksuchtigung des photochemischen Ab-baus. (Ph.D). Swiss Federal Institute of Technology.
- ^ Frank, R; Rau, H (1989). "Photochemical transformation in aqueous solution and possible environmental fate of Ethylenediaminetetraacetatic acid (EDTA)". Ecotoxicology and Environmental Safety 19 (1): 55–63. doi:10.1016/0147-6513(90)90078-j. PMID 2107071.
- ^ Kaluza, U; Klingelhofer, P; K, Taeger (1998). "Microbial degradation of EDTA in an industrial wastewater treatment plant". Water Research 32 (9): 2843–2845. doi:10.1016/S0043-1354(98)00048-7.
- ^ VanGinkel, C.G; Vandenbroucke, K.L; C.A, Troo (1997). "Biological removal of EDTA in conventional activated-sludge plants operated under alkaline conditions". Bioresources Technology 32 (2–3): 2843–2845. doi:10.1016/S0960-8524(96)00158-7.
- ^ Lauff, J.J.; Steele, D.B.; Coogan, L.A.; Breitfeller, J.M. (1990). "Degradation of the ferric chelate of EDTA by a pure culture of an Agrobacterium sp.". Applied and Environmental Microbiology 56 (11): 3346–3353. PMC 184952. PMID 16348340.
- ^ a b Nortemannl, B (1992). "Total degradation of EDTA by mixed culturesand a bacterial isolate" (PDF). Applied and Environmental Microbiology 58 (2): 671–676. PMC 195300. PMID 16348653.
- ^ Witschel, M., Weilemann, H.-U. and Egli, T. (1995). Degradation of EDTA by a bacterial isolate. Poster presented at the 45th Annual Meeting of the Swiss Society for Microbiology (Speech). Lugano, Switzerland.
- ^ Hennekenl, L; Nortemann, B; Hempel, D.C. (1995). "Influence of physiological conditions on EDTA degradation". Applied and Environmental Microbiology 44: 190–197. doi:10.1007/bf00164501.
- ^ a b c d e f g h i "Chelating Agents of a New Generation as an Alternative to Conventional Chelators for Heavy Metal Ions Removal from Different Waste Waters" (PDF). InTech. Retrieved 2013-12-12.
- ^ Cokesa, Z.; Knackmuss, H.; Rieger P. (2004), "Biodegradation of All Stereoisomers of the EDTA Substitute Iminodisuccinate by Agrobacterium Tumefaciens BY6 Requires an Epimerase and a Stereoselective C–N Lyase", Appl. Environ. Microbiol. 70 (7): 3941–3947, doi:10.1128/aem.70.7.3941-3947.2004, PMC 444814, PMID 15240267
- ^ a b Sheppard, R. L.; Henion, J. (1997). "Peer Reviewed: Determining EDTA in Blood". Analytical Chemistry 69 (15): 477A. doi:10.1021/ac971726p. PMID 9253241.
- ^ Loyaux-Lawniczak, S.; Douch, J.; Behra, P. (1999). "Optimisation of the analytical detection of EDTA by HPLC in natural waters". Fresenius' Journal of Analytical Chemistry 364 (8): 727. doi:10.1007/s002160051422.
- ^ Cagnasso, C. E.; López, L. B.; Rodríguez, V. G.; Valencia, M. E. (2007). "Development and validation of a method for the determination of EDTA in non-alcoholic drinks by HPLC". Journal of Food Composition and Analysis 20 (3–4): 248. doi:10.1016/j.jfca.2006.05.008.
External links
- The MEROPS online database for peptidases and their inhibitors: EDTA
- Lanigan RS; Yamarik TA (2002). "Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA". Int. J. Toxicol. 21 Suppl 2 (5): 95–142. doi:10.1080/10915810290096522. PMID 12396676.
- EDTA: Molecule of the Month
- EDTA Determination of Total Water Hardness
- EDTA: the chelating agent under environmental scrutiny, Química Nova, Nov–Dec 2003 (text version)
- EDTA: the chelating agent under environmental scrutiny, Química Nova, Nov–Dec 2003 (PDF version)
Antidotes (V03AB)
|
|
Nervous
system |
Nerve agent /
Organophosphate
poisoning
|
- Atropine#
- Biperiden
- Diazepam#
- Oximes
- see also: Cholinesterase
|
|
Barbiturate
overdose
|
|
|
Benzodiazepine
overdose
|
|
|
GHB overdose
|
|
|
Opioid overdose
|
- Diprenorphine
- Doxapram
- Nalmefene
- Nalorphine
- Naloxone#
- Naltrexone
|
|
Reversal of
neuromuscular blockade
|
|
|
|
Circulatory
system |
Beta blocker
|
|
|
Digoxin toxicity
|
|
|
Heparin
|
|
|
|
Other |
Arsenic poisoning
|
|
|
Cyanide poisoning
|
- 4-Dimethylaminophenol
- Hydroxocobalamin
- nitrite
- Amyl nitrite
- Sodium nitrite#
- Sodium thiosulfate#
|
|
Hydrofluoric acid
|
|
|
Methanol /
Ethylene glycol
poisoning
|
- Primary alcohols: Ethanol
- Fomepizole
|
|
Paracetamol toxicity
(Acetaminophen)
|
- Acetylcysteine#
- Glutathione
- Methionine#
|
|
|
- Dimercaprol#
- Edetates
- Prussian blue#
|
|
Other
|
- iodine-131
- Methylthioninium chloride#
- oxidizing agent
- Prednisolone/promethazine
|
|
|
Emetic |
- Copper sulfate
- Ipecacuanha
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
|
|
Antiplatelet drugs |
Glycoprotein IIb/IIIa inhibitors |
- Abciximab
- Eptifibatide
- Tirofiban
- Roxifiban
- Orbofiban
|
|
ADP receptor/P2Y12 inhibitors |
- Thienopyridines
- Clopidogrel
- Prasugrel
- Ticlopidine
- Nucleotide/nucleoside analogs
- Cangrelor
- Elinogrel
- Ticagrelor
|
|
Prostaglandin analogue (PGI2) |
- Beraprost
- Iloprost
- Prostacyclin
- Treprostinil
|
|
COX inhibitors |
- Acetylsalicylic acid/Aspirin#
- Aloxiprin
- Carbasalate calcium
- Indobufen
- Triflusal
|
|
Thromboxane inhibitors |
- Thromboxane synthase inhibitors
- Dipyridamole (+Aspirin)
- Picotamide
- Receptor antagonists
|
|
Phosphodiesterase inhibitors |
- Cilostazol
- Dipyridamole
- Triflusal
|
|
Other |
- Cloricromen
- Ditazole
- Vorapaxar
|
|
|
Anticoagulants |
Vitamin K antagonists
(inhibit II, VII, IX, X) |
- Coumarins: Acenocoumarol
- Coumatetralyl
- Dicoumarol
- Ethyl biscoumacetate
- Phenprocoumon
- Warfarin#
- 1,3-Indandiones: Clorindione
- Diphenadione
- Phenindione
- Other: Tioclomarol
|
|
Factor Xa inhibitors
(with some II inhibition) |
Heparin group/
glycosaminoglycans/
(bind antithrombin) |
- Low molecular weight heparin
- Bemiparin
- Certoparin
- Dalteparin
- Enoxaparin
- Nadroparin
- Parnaparin
- Reviparin
- Tinzaparin‡
- Oligosaccharides
- Fondaparinux
- Idraparinux§
- Heparinoids
- Danaparoid
- Dermatan sulfate
- Sulodexide
|
|
Direct Xa inhibitors |
- Xabans
- Apixaban
- Betrixaban†
- Darexaban§
- Edoxaban
- Otamixaban§
- Rivaroxaban
|
|
|
Direct thrombin (IIa) inhibitors |
- Bivalent: Hirudin
- Bivalirudin
- Desirudin
- Lepirudin
- Univalent: Argatroban
- Dabigatran
- Melagatran‡
- Ximelagatran‡
|
|
Other |
- Antithrombin III
- Defibrotide
- Protein C
- Ramatroban
- REG1
|
|
|
Thrombolytic drugs/
fibrinolytics |
- Plasminogen activators: r-tPA
- Alteplase
- Reteplase
- Tenecteplase
- UPA
- Anistreplase
- Monteplase
- Streptokinase#
- Other serine endopeptidases: Ancrod
- Brinase
- Fibrinolysin
|
|
Non-medicinal |
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Chelating agents / chelation therapy (V03AC, others)
|
|
Copper |
|
|
Iron |
- Deferasirox
- Deferiprone
- Deferoxamine#
|
|
Lead |
|
|
Thallium |
|
|
Other |
- ALA
- BAPTA
- DMPS
- DMSA
- DTPA
- EGTA
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
Endodontology (ICD-9-CM V3 23.0–23.2+23.7, ICD-10-PCS 0C?W–X)
|
|
Tests |
- Dental radiography
- Electric pulp test
|
|
Tools |
- Amalgam
- Dental dam
- EDTA
- Electronic apex locator
- Eucalyptol
- Files and reamers
- Gutta-percha
- Operating microscope
- Rotary technology
- Saline
- Silverpoints
- Sodium hypochlorite
|
|
Procedures |
- Apicoectomy
- Endodontic retreatment
- Endodontic therapy
- Regenerative endodontics
- Internal bleaching
- Pulpotomy
- Pulp capping
|
|
Protein and peptide receptor modulators
|
|
Adiponectin |
AdipoR1
|
- Agonists: Peptide: Adiponectin
- ADP-355
- ADP-399; Non-peptide: AdipoRon
- (–)-Arctigenin
- Arctiin
- Gramine
- Matairesinol
- Antagonists: Peptide: ADP-400
|
|
AdipoR2
|
- Agonists: Peptide: Adiponectin
- ADP-355
- ADP-399; Non-peptide: AdipoRon
- Deoxyschizandrin
- Parthenolide
- Syringing
- Taxifoliol
- Antagonists: Peptide: ADP-400
|
|
|
Angiotensin |
- Agonists: Angiotensin II
- Angiotensin III
- Angiotensin IV
- Saralasin
- Antagonists: Abitesartan
- Azilsartan
- Azilsartan medoxomil
- Candesartan
- Elisartan
- Embusartan
- Eprosartan
- EXP-3174
- Fimasartan
- Forasartan
- Irbesartan
- Losartan
- Milfasartan
- Olmesartan
- Olmesartan medoxomil
- PD123319
- Pomisartan
- Pratosartan
- Ripisartan
- Saprisartan
- Sparsentan
- Tasosartan
- Telmisartan
- Valsartan
- Zolasartan
- ACE inhibitors: Alacepril
- Benazepril
- Captopril
- Cilazapril
- Delapril
- Enalapril
- Enalaprilat
- Fosinopril
- Gemopatrilat
- Imidapril
- Lisinopril
- Moexipril
- Omapatrilat
- Perindopril
- Quinapril
- Quinaprilat
- Ramipril
- Rentiapril
- Rescinnamine
- Spirapril
- Spiraprilat
- Temocapril
- Trandolapril
- Zofenopril
- Zofenoprilat
- Renin inhibitors: Aliskiren
- Ciprokiren
- Ditekiren
- Enalkiren
- Pepstatin
- Remikiren
- Terlakiren
- Zankiren
- Propeptides: Angiotensinogen
- Angiotensin I
|
|
Bradykinin |
- Agonists: Bradykinin
- Kallidin
- Antagonists: FR-173657
- Icatibant
- LF22-0542
|
|
CGRP |
- Agonists: Amylin
- CGRP
- Pramlintide
- Antagonists: BI 44370 TA
- BMS-927711
- CGRP (8-37)
- MK-3207
- Olcegepant
- Rimegepant
- SB-268262
- Telcagepant
- Ubrogepant
|
|
Cholecystokinin |
CCKA
|
- Agonists: Cholecystokinin
- CCK-4
- Antagonists: Amiglumide
- Asperlicin
- Devazepide
- Dexloxiglumide
- Lintitript
- Lorglumide
- Loxiglumide
- Pranazepide
- Proglumide
- Tarazepide
- Tomoglumide
|
|
CCKB
|
- Agonists: Cholecystokinin
- CCK-4
- Gastrin
- Antagonists: CI-988 (PD-134308)
- Itriglumide
- L-365,360
- Netazepide
- Proglumide
- Spiroglumide
|
|
Unsorted
|
- Antagonists: Nastorazepide
|
|
|
CRH |
CRF1
|
- Agonists: Cortagine
- Corticorelin
- Corticotropin releasing hormone
- Sauvagine
- Stressin I
- Urocortin
- Antagonists: Antalarmin
- Astressin-B
- CP-154,526
- Emicerfont
- Hypericin
- LWH-234
- NBI-27914
- Pexacerfont
- R-121919
- TS-041
- Verucerfont
|
|
CRF2
|
- Agonists: Corticorelin
- Corticotropin releasing hormone
- Sauvagine
- Urocortin
|
|
|
Cytokine |
See here instead.
|
|
Endothelin |
- Agonists: Endothelin 1
- Endothelin 2
- Endothelin 3
- IRL-1620
- Antagonists: A-192621
- ACT-132577
- Ambrisentan
- Atrasentan
- Avosentan
- Bosentan
- BQ-123
- BQ-788
- Clazosentan
- Darusentan
- Edonentan
- Enrasentan
- Fandosentan
- Feloprentan
- Macitentan
- Nebentan
- Sitaxentan
- Sparsentan
- Tezosentan
- Zibotentan
|
|
Galanin |
GAL1
|
- Agonists: Galanin
- Galanin (1-15)
- Galanin-like peptide
- Galmic
- Galnon
- Antagonists: C7
- Dithiepine-1,1,4,4-tetroxide
- Galantide (M15)
- M32
- M35
- M40
- SCH-202596
|
|
GAL2
|
- Agonists: Galanin
- Galanin (1-15)
- Galanin (2-11)
- Galanin-like peptide
- Galmic
- Galnon
- J18
- Antagonists: C7
- Galantide (M15)
- M32
- M35
- M40
- M871
|
|
GAL3
|
- Agonists: Galanin
- Galanin (1-15)
- Galmic
- Galnon
- Antagonists: C7
- Galantide (M15)
- GalR3ant
- HT-2157
- M32
- M35
- M40
- SNAP-37889
- SNAP-398299
|
|
|
Ghrelin/GHS |
- Agonists: Peptide: Alexamorelin
- Cortistatin-14
- Examorelin (hexarelin)
- Ghrelin
- GHRP-1
- GHRP-3
- GHRP-4
- GHRP-5
- GHRP-6
- Ipamorelin
- Lenomorelin
- Pralmorelin (GHRP-2)
- Relamorelin
- Tabimorelin
- Ulimorelin; Non-peptide: Adenosine
- Anamorelin
- Capromorelin
- CP-464709
- Ibutamoren (MK-677)
- L-692,585
- Macimorelin
- SM-130686; Unsorted: LY-426410
- LY-444711
- Antagonists: A-778193
- Cortistatin-8
- (D-Lys³)-GHRP-6
- JMV2959
- YIL-781
- Binding proteins: Growth hormone-binding protein
|
|
GH |
- Agonists: Bovine somatotropin
- Efpegsomatropin
- Growth hormone
- Human placental lactogen
- MOD-4023
- Somagrebove
- Somapacitan
- Somatosalm
- Somatotropin
- Somatropin pegol
- Somatrem
- Sometribove
- Somavaratan
- Somavubove
- Somidobove
- Antagonists: G120K-hGH
- Pegvisomant
|
|
GHRH |
- Agonists: Peptide: CJC-1295
- Dumorelin
- GHRH
- Modified GRF (1-29)
- Rismorelin
- Sermorelin
- Somatorelin
- Tesamorelin
|
|
GLP |
GLP-1
|
- Agonists: Albiglutide
- Dulaglutide
- Efpeglenatide
- Exenatide
- GLP-1
- Langlenatide
- Liraglutide
- Lixisenatide
- Oxyntomodulin
- Semaglutide
- Taspoglutide
|
|
GLP-2
|
- Agonists: Elsiglutide
- GLP-2
- Teduglutide
|
|
Others
|
- Propeptides: Preproglucagon
- Proglucagon
|
|
|
Glucagon |
- Agonists: Glucagon
- Oxyntomodulin
- Antagonists: L-168,049
- LGD-6972
- Propeptides: Preproglucagon
- Proglucagon
|
|
GnRH |
- Agonists: Peptide: Avorelin
- Buserelin
- Deslorelin
- Gonadorelin
- GnRH (LHRH)
- Goserelin
- Histrelin
- Leuprorelin
- Lutrelin
- Nafarelin
- Peforelin
- Triptorelin
- Zoptarelin doxorubicin
- Antagonists: Peptide: Abarelix
- Acyline
- Cetrorelix
- Degarelix
- Detirelix
- Ganirelix
- Iturelix
- Ozarelix
- Prazarelix
- Ramorelix
- Teverelix (antarelix); Non-peptide: ASP-1707
- Elagolix
- KLH-2109
- Relugolix
- Sufugolix
|
|
Gonadotropin |
LH/CG
|
- Agonists: Choriogonadotropin alfa
- Human chorionic gonadotropin
- Luteinizing hormone
- Lutropin alfa
- Menotropin (human menopausal gonadotropin)
|
|
FSH
|
- Agonists: Corifollitropin alfa
- Follicle-stimulating hormone
- Follitropin alfa
- Follitropin beta
- Menotropin (human menopausal gonadotropin)
- Urofollitropin
- Varfollitropin alfa
|
|
|
Growth factor |
See here instead.
|
|
Insulin |
- Agonists: Insulin-like growth factor 1
- Insulin-like growth factor 2
- Insulin
- Insulin aspart
- Insulin degludec
- Insulin detemir
- Insulin glargine
- Insulin glulisine
- Insulin lispro
- Mecasermin
- Mecasermin rinfabate
- Antagonists: BMS-754807
- S661
- S961
- Kinase inhibitors: Linsitinib
|
|
Kisspeptin |
- Agonists: Kisspeptin
- Kisspeptin-10
- Antagonists: Kisspeptin-234
|
|
Leptin |
- Agonists: Leptin
- Metreleptin
|
|
MCH |
MCH1
|
- Agonists: Melanin concentrating hormone
- Antagonists: ATC-0065
- ATC-0175
- GW-803430
- NGD-4715
- SNAP-7941
- SNAP-94847
|
|
MCH2
|
- Agonists: Melanin concentrating hormone
|
|
|
Melanocortin |
|
|
Neuropeptide FF |
- Agonists: Neuropeptide AF
- Neuropeptide FF
- Neuropeptide SF (RFRP-1)
- Neuropeptide VF (RFRP-3)
- Antagonists: BIBP-3226
- RF9
|
|
Neuropeptide S |
- Antagonists: ML-154
- SHA-68
|
|
Neuropeptide Y |
Y1
|
- Agonists: Neuropeptide Y
- Peptide YY
- Antagonists: BIBO-3304
- BIBP-3226
- BVD-10
- GR-231118
- PD-160170
|
|
Y2
|
- Agonists: 2-Thiouridine 5'-triphosphate
- Neuropeptide Y
- Neuropeptide Y (13-36)
- Peptide YY
- Peptide YY (3-36)
- Antagonists: BIIE-0246
- JNJ-5207787
- SF-11
|
|
Y4
|
- Agonists: GR-231118
- Neuropeptide Y
- Pancreatic polypeptide
- Peptide YY
|
|
Y5
|
- Agonists: BWX-46
- Neuropeptide Y
- Peptide YY
- Antagonists: CGP-71683
- FMS-586
- L-152,804
- Lu AA-33810
- MK-0557
- NTNCB
- Velneperit (S-2367)
|
|
|
Neurotensin |
NTS1
|
- Agonists: Neurotensin
- Neuromedin N
- Antagonists: Meclinertant
- SR-142948
|
|
NTS2
|
- Antagonists: Levocabastine
- SR-142948
|
|
|
Opioid |
See here instead.
|
|
Orexin |
OX1
|
- Antagonists: ACT-335827
- ACT-462206
- Almorexant
- Filorexant
- Lemborexant
- SB-334867
- SB-408124
- SB-649868
- Suvorexant
- TCS-1102
|
|
OX2
|
- Agonists: Orexin (A, B)
- SB-668875
- Antagonists: ACT-335827
- ACT-462206
- Almorexant
- EMPA
- Filorexant
- JNJ-10397049
- MIN-202 (JNJ-42847922)
- Lemborexant
- MK-1064
- SB-649868
- Suvorexant
- TCS-1102
- TCS-OX2-29
|
|
|
Oxytocin |
|
|
Prolactin |
- Agonists: Growth hormone
- Human placental lactogen
- Prolactin
- S179D-hPRL
- Somatotropin
- Antagonists: Δ1–9-G129R-hPRL
- Δ1–14-G129R-hPRL
- G120K-hGH
- G129R-hPRL
|
|
PTH |
- Agonists: Abaloparatide
- Parathyroid hormone
- Parathyroid hormone-related protein (PTHrP)
- Semparatide
- Teriparatide
|
|
Relaxin |
- Agonists: Insulin-like factor 3
- Relaxin (1, 2, 3)
- Serelaxin
|
|
Somatostatin |
- Agonists: BIM-23052
- CH-275
- Cortistatin-14
- Depreotide
- Ilatreotide
- L-803,087
- L-817,818
- Lanreotide
- NNC 26-9100
- Octreotide
- Pasireotide
- Pentetreotide
- RC-160
- Seglitide
- Somatostatin (GHIH)
- Somatostatin (1-28)
- SRIF-14
- SRIF-28
- TT-232
- Vapreotide
- Antagonists: BIM-23056
- Cyclosomatostatin
- CYN-154806
|
|
Tachykinin |
NK1
|
- Antagonists: Aprepitant
- Befetupitant
- Burapitant
- Casopitant
- CI-1021
- CP-96345
- CP-99994
- CP-122721
- Dapitant
- Ezlopitant
- Figopitant
- FK-888
- Fosaprepitant
- Fosnetupitant
- GR-203040
- GW-597599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium besilate
- Orvepitant
- Rolapitant
- RP-67580
- SDZ NKT 343
- Serlopitant
- Telmapitant
- Tradipitant
- Vestipitant
- Vofopitant
|
|
NK2
|
- Antagonists: GR-159897
- Ibodutant
- Nepadutant
- Saredutant
|
|
NK3
|
- Antagonists: Osanetant
- Talnetant
|
|
|
TRH |
- Agonists: Azetirelin
- Fertirelin
- Montirelin
- Orotirelin
- Posatirelin
- Protirelin
- Rovatirelin
- Taltirelin
- TRH (TRF)
|
|
TSH |
- Agonists: Thyrotropin alfa
- TSH (thyrotropin)
|
|
Vasopressin |
|
|
VIP/PACAP |
VIPR1
|
- Agonists: Peptide: Bay 55-9837
- LBT-3393
- PACAP
- VIP
|
|
VIPR2
|
- Agonists: Peptide: LBT-3627
- PACAP
- VIP
|
|
PAC1
|
- Agonists: PACAP
- PACAP (1-27)
- PACAP (1-38)
- Antagonists: PACAP (6-38)
|
|
Unsorted
|
|
|
|
Others |
- Adrenomedullin
- Apelin
- Bombesin
- Calcitonin
- Carnosine
- CART
- CLIP
- DSIP
- Enteroglucagon
- Formyl peptide
- GALP
- GIP
- GRP
- Integrin ligands (collagens, fibrinogen, fibronectin, laminins, ICAM-1, ICAM-2, osteopontin, VCAM-1, vitronectin)
- Kininogens
- Motilin
- Natriuretic peptides (ANP, BNP, CNP, urodilatin)
- Nesfatin-1
- Neuromedin B
- Neuromedin N
- Neuromedin S
- Neuromedin U
- Obestatin
- Osteocalcin
- Resistin
- Secretin
- Thymopoietin
- Thymosins
- Thymulin
- Urotensin-II
- VGF
|
|